Almirall reports encouraging results from Phase II study of asthma drug
The multi-dose, placebo-controlled, three-period cross-over study, included 20 stable asthmatic patients. LAS 100977 demonstrated 24 hour bronchodilation and sustained efficacy during multiple dose administrations with no significant increase
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.